BioSpace News Archive

Additive Orthopaedics, LLC., announced today it has received an approval order from the U.S. Food and Drug Administration (“FDA”) for its Humanitarian Device Exemption (“HDE”)

NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response, today announced the closing of its previously announced upsized initial public offering of 7,441,650 shares of its common stock at a price to the public of $17.00 per share

ESSA Pharma Inc., a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, announced the pricing of an underwritten public offering of 4,830,918 common shares at a public offering price of $27.00 per share, before underwriting discounts, for an aggregate offering of approximately $130.4 million.

Fact.MR, Rockville: The global contouring products market study has been released by award-winning market research firm Fact.MR.

Fact.MR, a global research & consulting firm, in their latest edition of the report, indicated that the cephalic disorders treatment market is poised to witness a steady growth in 2021 and beyond.